Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

August 31, 2011

Conditions
Esophageal Cancer
Interventions
DRUG

Erlotinib

Erlotinib

DRUG

Bevacizumab

Bevacizumab

DRUG

Paclitaxel

Paclitaxel

DRUG

Carboplatin

Carboplatin

DRUG

5-FU

5-FU

PROCEDURE

Radiation therapy

Radiation therapy

PROCEDURE

Surgery

Surgery

Trial Locations (9)

30501

Northeast Georgia Medical Center, Gainesville

32256

Integrated Community Oncology Network, Jacksonville

33901

Florida Cancer Specialists, Fort Myers

37023

Tennessee Oncology, PLLC, Nashville

37404

Chattanooga Oncology Hematology Associates, Chattanooga

40207

Consultants in Blood Disorders and Cancer, Louisville

44710

Aultman Hospital, Canton

45242

Oncology Hematology Care, Cincinnati

07960

Hematology Oncology Associates of Northern NJ, Morristown

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER